Treatment regimen for each cycle
. | Screening . | day 1 . | day 3 . | day 4 . | day 14 . | day 16 . | day 17 . | day 28 . |
|---|---|---|---|---|---|---|---|---|
| IFN-α 9 Mio U subcutaneously | NA | x | x | ND | x | x | ND | ND |
| Measles virus intratumorally | NA | ND | ND | x | ND | ND | x | ND |
| Punch biopsy | x | ND | ND | ND | ND | ND | ND | x |
. | Screening . | day 1 . | day 3 . | day 4 . | day 14 . | day 16 . | day 17 . | day 28 . |
|---|---|---|---|---|---|---|---|---|
| IFN-α 9 Mio U subcutaneously | NA | x | x | ND | x | x | ND | ND |
| Measles virus intratumorally | NA | ND | ND | x | ND | ND | x | ND |
| Punch biopsy | x | ND | ND | ND | ND | ND | ND | x |
Each treatment cycle consisted of 2 intratumoral injections of the measles virus (day 4 and day 17). Injections of IFN-α (9 Mio U subcutaneously) were administered 72 hours and 24 hours before each of the measles-virus injections. At screening and on day 28 a tumor biopsy was taken.
NA indicates not applicable; ND, not done.